BPC-157 and TB-500
BPC-157 and TB-500 are the most popular recovery pairing in peptide research, usually run together as a "blend." The rationale is that they're complementary — BPC-157 is studied for local repair (tendon, gut), while TB-500 (a thymosin β-4 fragment) is framed as more systemic.[2] The honest caveat throughout: the BPC-157 and TB-500 stack is a community and marketing convention — there is no controlled human trial of the combination, and neither peptide is FDA-approved. TB-500 is also WADA-banned.
What is the BPC-157 and TB-500 blend?
The BPC-157 and TB-500 blend is the two peptides used together — sometimes as a single combined vial, sometimes as separate vials on the same schedule — for recovery research.[1]
They're paired because their research stories point in complementary directions. BPC-157 is a gastric peptide studied for localised tissue and gut repair;[3] TB-500 is the actin-binding fragment of thymosin β-4, framed as supporting more systemic, whole-body recovery through cell migration and blood-vessel growth.[2] Combining them is meant to cover both the local and the systemic side of repair.
BPC-157 + TB-500 capsules, nasal & injectable
The blend is sold in a few formats — injectable (the most common, and the one the research mechanisms assume), capsules, and nasal sprays. It's worth a flag that oral and nasal peptide delivery is far less certain than injection: both BPC-157 and TB-500 are peptides, and capsule or spray bioavailability for TB-500 in particular is poor, so those formats are convenience-driven, not evidence-backed.
BPC-157 and TB-500 benefits
The benefits attributed to the BPC-157 and TB-500 blend are recovery-focused: faster soft-tissue, tendon and muscle repair, reduced inflammation, and better resilience to injury.[4][2] The appeal of the stack is the idea of two mechanisms working together — BPC-157's local repair plus TB-500's systemic, migration-and-angiogenesis support.
Why the BPC-157 and TB-500 stack is used
Researchers and athletes reach for the combination on the logic that recovery isn't one process — it's local healing and systemic tissue turnover — so a peptide for each is meant to be more complete than either alone. That logic is reasonable, but it's important to separate it from evidence: BPC-157's data is largely animal,[3] TB-500's is thymosin-β-4 animal work,[2] and the combination has never been tested in a controlled trial. The synergy is plausible and popular, not proven.
tuned TB-500
For laboratory research use only · available to researchers. Specifications, pricing & Certificate of Analysis on the product page.
BPC-157 + TB-500 blend dosage
There's no established dose for the BPC-157 and TB-500 blend — no trial has set one for either peptide, let alone the combination.[1] There is no established human dose for either compound; community protocols describe running them on their own conventional schedules, but those figures are unverified vendor/forum conventions and are not provided here. These are vendor and forum conventions, unverified.
BPC-157 + TB-500 blend ratio & calculator
Blend products are often sold at a 1:1 or 2:1 ratio of the two peptides, but ratios are marketing choices, not evidence-based formulas. Because the two are reconstituted together or run together in a protocol, this page does not provide dosing, measurement, or administration guidance for either compound.
Is the BPC-157 and TB-500 stack worth it?
"Is it worth it?" depends on what you mean. As a research question it's a reasonable pairing — two complementary repair mechanisms, both with supportive (if preclinical) rationale.[2][3] As a proven recovery treatment, no: there's no human trial of either peptide's efficacy, none of the combination, and both are sold for research use only.
BPC-157 and TB-500: the honest verdict
The honest verdict is that the stack is popular and mechanistically coherent but evidentially unproven — and carries real caveats: TB-500 is WADA-banned for athletes, neither peptide is FDA-approved, and material quality (endotoxin, purity) is the dominant real-world risk for both. For a head-to-head of the two on their own, see the BPC-157 vs TB-500 comparison.
Common questions
What is the BPC-157 and TB-500 blend?
What are the benefits of the BPC-157 and TB-500 stack?
What is the BPC-157 + TB-500 blend dosage?
Is the BPC-157 and TB-500 stack worth it?
Can you take BPC-157 and TB-500 in capsules or nasal spray?
References
- Esposito S, Deventer K, Goeman J, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Testing and Analysis, 2012;4(9):733–738. PMID 22962027.
- Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. Journal of Investigative Dermatology, 1999;113(3):364–368. PMID 10469335. (Tβ4, rat wound model.)
- Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design, 2011;17(16):1612–1632. PMID 21548867.
- Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 2019;377(2):153–159. PMID 30915550.
TB-500 is the Tβ4 fragment [1]; cited recovery mechanisms are thymosin β-4 (animal) [2] and BPC-157 (largely animal) [3,4]. There is no controlled trial of either peptide efficacy or of the BPC-157 + TB-500 combination — the stack is a community/marketing convention. Neither is FDA-approved; TB-500 is WADA-banned. Not medical advice.
For research use only. Not for human consumption. This page summarises published research for educational purposes. It is not medical advice and is not intended to diagnose, treat, cure, or prevent any disease.
